TNFα and IL-32 have both been shown to induce each other in a positive feedback loop in arthritis in PBMCs, lymphoid tissue and DCs (62) again suggesting that the effects of Golimumab and other immunotherapies targeting TNFα to slow T1D progression may involve suppression of IL-32 (70, 71). This evidence concerns the gene IL32 and arthritic joint disease.